DMH1: Selective BMP Type I Receptor Inhibitor for Cancer and Organoid Research

Executive Summary: DMH1 (B3686) is a highly selective small-molecule inhibitor of BMP type I receptors, exhibiting an IC50 of 107.9 nM for ALK2 and submicromolar potency for ALK3, with no activity against VEGF signaling or kinases such as KDR, ALK5, AMPK, and PDGFRβ (APExBIO product datasheet). It enables robust suppression of Smad1/5/8 phosphorylation and Id gene expression in non-small cell lung cancer (NSCLC) models, resulting in reduced tumor growth and increased cell death in vivo and in vitro (Yang et al., 2025). DMH1's selectivity permits high-fidelity modulation of BMP signaling in complex models, including human intestinal organoids, without promoting off-target differentiation or proliferation (DMH1: Selective BMP Type I Receptor Inhibitor for Cancer ...). APExBIO's validated supply ensures consistency across research applications, from tumor xenograft studies to high-throughput organoid screens. The compound is insoluble in water and ethanol but highly soluble in DMSO, and should be stored at -20°C for stability (product page).

Biological Rationale

Bone morphogenetic protein (BMP) signaling is a critical pathway regulating embryogenesis, organogenesis, and adult tissue homeostasis. BMP receptors, particularly type I receptors ALK2 (ACVR1) and ALK3 (BMPR1A), mediate the phosphorylation of Smad1/5/8 proteins, leading to transcriptional regulation of genes involved in cell fate, proliferation, and differentiation (Yang et al., 2025). Aberrant BMP signaling is implicated in tumorigenesis, notably in non-small cell lung cancer (NSCLC), where excessive BMP activity enhances tumor cell migration, invasion, and survival. In stem cell-derived organoid models, precise modulation of BMP signaling is essential to balance stem cell self-renewal and differentiation, as demonstrated by recent breakthroughs in tunable organoid systems (Yang et al., 2025). Conventional BMP inhibitors lack selectivity, confounding experiments due to off-target effects. DMH1 was developed as a dorsomorphin analog to provide potent, specific inhibition of BMP type I receptors, enabling refined dissection of BMP-dependent processes in both cancer and regenerative research (DMH1: A Selective BMP Type I Receptor Inhibitor in Advanc...—this article details advanced organoid use cases, while the current article focuses on translational cancer benchmarks and workflow integration).

Mechanism of Action of DMH1

DMH1 is a small molecule that binds to the ATP-binding site of BMP type I receptors, with selectivity for ALK2 (IC50 = 107.9 nM) and ALK3 (IC50 < 0.5 μM). It competitively inhibits receptor-mediated phosphorylation of Smad1/5/8, blocking downstream transcriptional activation of BMP target genes such as Id1, Id2, and Id3. Unlike broader kinase inhibitors, DMH1 does not inhibit VEGF receptor KDR, ALK5, AMPK, PDGFRβ, p38/MAP kinase, or Activin A-induced Smad2 signaling, ensuring pathway specificity (APExBIO). In cellular assays, DMH1 suppresses BMP-induced gene expression without affecting unrelated signaling cascades. This selectivity enables researchers to attribute observed phenotypes directly to BMP pathway modulation. In NSCLC models, DMH1 treatment leads to reduced cell migration, invasion, proliferation, and increased apoptosis. In organoid systems, DMH1 can shift the balance between stemness and differentiation without introducing confounding off-target effects (Redefining Translational Research: Mechanistic Insights a...—the linked article provides mechanistic details, while the current piece includes explicit experimental benchmarks and workflow guidance).

Evidence & Benchmarks

• DMH1 inhibits ALK2 with an IC50 of 107.9 nM and ALK3 with an IC50 below 0.5 μM in in vitro kinase assays (APExBIO).
• DMH1 does not inhibit VEGF signaling, KDR, ALK5, AMPK, or PDGFRβ at concentrations up to 10 μM (APExBIO, product page).
• In A549 NSCLC xenograft mice, DMH1 at validated doses extends tumor doubling time and reduces tumor volume by ~50% compared to vehicle control; effect is associated with decreased Smad1/5/8 phosphorylation and Id1/2/3 transcript levels (Yang et al., 2025).
• In human intestinal organoids, DMH1 enables reversible and controlled shifts in stem cell self-renewal and differentiation, enhancing cellular diversity without artificial niche gradients (Yang et al., 2025).
• DMH1 is insoluble in water and ethanol but soluble in DMSO at ≥9.51 mg/mL; optimal handling requires dissolution at 37°C with ultrasonic shaking (APExBIO).
• APExBIO's DMH1 supply is validated for research use only and maintains stability at -20°C for extended periods (APExBIO).

Applications, Limits & Misconceptions

DMH1 is employed in cancer models, regenerative biology, and organoid engineering to interrogate BMP pathway functions. In NSCLC, it allows precise dissection of tumor-promoting BMP signaling and quantification of anti-migratory and anti-proliferative effects (DMH1: Selective BMP Type I Receptor Inhibitor for Organoi...—this prior article emphasizes stem cell applications; the current work updates with in vivo cancer benchmarks and handling guidance). In organoid systems, DMH1 supports scalable, high-fidelity screens where BMP modulation is required for fate mapping or therapeutic testing. Its high selectivity minimizes off-target effects, improving reproducibility compared to legacy inhibitors.

Common Pitfalls or Misconceptions

• DMH1 is inactive against non-BMP kinases, including ALK5, AMPK, and VEGF receptor KDR—use in non-BMP pathway studies may yield no effect (APExBIO).
• DMH1 is not water- or ethanol-soluble; improper solvent use can cause precipitation and loss of activity (APExBIO).
• Long-term solutions at room temperature are unstable; storage at -20°C and prompt use after reconstitution are essential for reproducibility.
• In vivo, DMH1 efficacy may be limited by pharmacokinetic factors—systemic administration in models should be empirically optimized.
• DMH1 does not induce differentiation or proliferation in isolation; its effects are context-dependent and require BMP pathway activity.

Workflow Integration & Parameters

For optimal solubility, DMH1 should be dissolved in DMSO at concentrations ≥9.51 mg/mL, with warming to 37°C and ultrasonic shaking if needed (DMH1 product page). It is available from APExBIO as a solid powder or 10 mM DMSO solution. Stock solutions should be stored at -20°C and aliquoted to minimize freeze-thaw cycles. In cellular assays, working concentrations typically range from 100 nM to 1 μM, depending on cell type and endpoint. In vivo dosing regimens must be titrated for each animal model and application. DMH1 is compatible with high-throughput organoid screens, as demonstrated in systems that require tunable BMP inhibition to balance self-renewal and differentiation (Yang et al., 2025).

Conclusion & Outlook

DMH1 has established itself as the gold-standard selective BMP type I receptor inhibitor for both cancer and organoid research. Its nanomolar potency and high specificity for ALK2 and ALK3 enable detailed mechanistic studies without off-target confounds. As organoid and tumor models continue to evolve, DMH1 will remain central for high-fidelity pathway modulation, supporting reproducible discoveries in cell fate, regeneration, and tumor suppression. For additional information, protocols, and product specifications, see the DMH1 (B3686) product page at APExBIO.